Financial Performance - The company's operating revenue for 2024 was ¥445,864,331.31, a decrease of 32.75% compared to ¥663,025,874.35 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥91,547,379.78, down 48.02% from ¥176,116,201.67 in 2023[22]. - The basic earnings per share for 2024 was ¥0.32, a decline of 47.54% from ¥0.61 in 2023[22]. - The total assets at the end of 2024 were ¥2,488,655,694.01, a decrease of 2.27% from ¥2,546,570,975.79 at the end of 2023[22]. - The company reported a cash flow from operating activities of ¥96,073,242.89 in 2024, down 29.91% from ¥137,063,475.71 in 2023[22]. - The company’s net profit after deducting non-recurring gains and losses for 2024 was ¥72,955,012.10, a decrease of 57.14% from ¥170,236,321.77 in 2023[22]. - The weighted average return on equity for 2024 was 4.00%, down from 7.63% in 2023, a decline of 3.63%[22]. - The revenue from raw materials is ¥356,155,439.93, accounting for 79.88% of total revenue, down 35.78% from ¥554,613,468.87 in 2023[54]. - The revenue from formulations is ¥85,214,019.75, representing 19.11% of total revenue, a decrease of 17.57% from ¥103,376,153.77 in 2023[54]. - The gross margin for raw materials is 21.18%, down 14.92% year-on-year, while the gross margin for formulations is 59.48%, down 3.20% year-on-year[56]. Dividend Distribution - The company plans to distribute a cash dividend of 2.5 RMB per 10 shares to all shareholders, based on a total of 288 million shares[5]. - The board of directors has approved a profit distribution plan, with no bonus shares being issued[5]. - The company distributed a cash dividend of RMB 4.80 per 10 shares, totaling RMB 138,240,000.00, based on a total share capital of 288,000,000 shares[152]. Research and Development - R&D investment for the period was CNY 32,937,088.26, a decline of 37.59% compared to the previous year[44]. - The company is actively researching and developing various specialty APIs, including anti-tumor and cardiovascular drugs, to enrich its product line[47]. - The company has developed a series of ibuprofen derivative products to meet diverse customer needs and expand market reach[46]. - The company is in the trial production phase for new processes of R-enantiomer Ibuprofen, aiming to optimize production costs and enhance product competitiveness[66]. - Research and development (R&D) expenditure amounted to ¥32,937,088.26 in 2024, representing 7.39% of operating revenue, down from 7.96% in 2023[68]. Market and Product Development - The company focuses on the research, production, and sales of chemical raw materials and formulations, including non-steroidal anti-inflammatory drugs, cardiovascular drugs, and anti-tumor drugs[38]. - The company has established a contract development and manufacturing organization (CDMO) service to meet customer needs from preclinical to commercialization stages[38]. - The company is developing new products such as Torasemide injection and non-fluorobenzene tablets to enrich its product portfolio[67]. - The company aims to establish a global manufacturing base for ibuprofen and its derivatives, enhancing production capacity and product competitiveness[92]. - The company plans to develop a "specialty raw material drug manufacturing base" focusing on cardiovascular, anti-tumor, and anticholinergic drugs[92]. Environmental and Regulatory Compliance - The company has obtained multiple environmental protection approvals for various projects, including a 5,000-ton ibuprofen raw material project approved in July 2020[165]. - The company holds a valid pollution discharge permit, effective from December 28, 2020, to December 27, 2025[169]. - The company has received environmental impact report approvals for projects involving 1,200 tons of raw materials and 12 tons of anti-tumor raw materials in August 2024[168]. - The company has implemented necessary internal control measures to ensure compliance with national laws and regulations, preventing significant losses[160]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[188]. Corporate Governance - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal regulations and providing equal rights to all shareholders[106]. - The board of directors consists of 8 members, including 3 independent directors, and held 7 meetings during the reporting period, adhering to relevant laws and regulations[108]. - The supervisory board, comprising 3 members, conducted 6 meetings in accordance with legal requirements, effectively overseeing the company's operations and financial status[110]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, with no instances of fund occupation or guarantees provided to the controlling shareholder[113]. - The company is committed to maintaining high standards of corporate governance with the appointment of qualified independent directors[128]. Management and Personnel - The total number of employees at the end of the reporting period is 987, with 872 from the parent company and 115 from major subsidiaries[148]. - The employee composition includes 663 production personnel, 20 sales personnel, 147 technical personnel, 19 financial personnel, and 138 administrative personnel[149]. - The company has implemented a competitive and fair salary policy, regularly adjusting salaries based on company performance and market surveys[150]. - The company has a diverse management team with various educational backgrounds and professional experiences[130][132][133]. - The company reported a total remuneration for the board of directors, supervisors, and senior management in 2024 is 5.7176 million yuan[137]. Investment and Financial Management - The total investment during the reporting period reached ¥1,044,345,991.68, a significant increase of 4,779.38% compared to ¥21,403,233.73 in the previous year[74]. - The company reported a net cash flow from investment activities was -¥1,109,461,774.79, a deterioration of 434.76% compared to -¥207,468,705.16 in 2023[68]. - The company has allocated 90,000,000 CNY for cash management from idle raised funds, with 7,975,220 CNY deposited in a special account[79]. - The company has committed to investing 119 million in various projects, with a focus on enhancing operational efficiency[82]. - The company plans to increase the cash management limit for idle raised funds, which may enhance liquidity and investment flexibility[121].
亨迪药业(301211) - 2024 Q4 - 年度财报